<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-04-27">27 April 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Simon</forename><surname>Hellwig</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrike</forename><surname>Grittner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Biostatistics and Clinical Epidemiology</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heinrich</forename><surname>Audebert</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Endres</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Berlin Institute of Health</orgName>
								<address>
									<addrLine>Kapelle-Ufer 2</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">German Center for Neurodegenerative Diseases (DZNE)</orgName>
								<address>
									<addrLine>Partner Site Berlin</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Center for Cardiovascular Diseases (DZHK)</orgName>
								<address>
									<addrLine>Partner Site Berlin</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Karl</forename><forename type="middle">Georg</forename><surname>Haeusler</surname></persName>
							<email>georg.haeusler@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charite ´-Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Charite ´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-04-27">27 April 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">13065F677E017D3753F8B749C20D98CF</idno>
					<idno type="DOI">10.1093/europace/eux087</idno>
					<note type="submission">Received 23 December 2016; editorial decision 8 March 2017; accepted 8 March 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:48+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Several studies showed reduced stroke severity in patients with atrial fibrillation (AF) if the international normalized ratio (INR) was &gt; _ 2 at stroke onset.</s><s>There are no respective data for non-vitamin K-dependent oral anticoagulants (NOACs).</s><s>The aim of this study was to compare the impact of NOAC or phenprocoumon intake on stroke severity.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide.</s><s>AF increases the individual stroke risk about four-to five-fold, and at least 15% of all ischaemic strokes are caused by AF.</s><s>2]<ref type="bibr" target="#b3">[3]</ref> Four phase III studies have demonstrated that non-vitamin K-dependent oral anticoagulants (NOACs) are at least equally effective to the vitamin K antagonist (VKA) warfarin with a median time in therapeutic range between 58 and 68% in these trials. <ref type="bibr" target="#b4">4</ref></s><s>However, the use of oral anticoagulants is restricted by contraindications such as renal failure or previous bleeds.</s><s>In addition, the feared risk of bleeding leads to non-compliance with guideline recommendations. <ref type="bibr" target="#b5">5,</ref><ref type="bibr" target="#b6">6</ref></s><s>Consecutively, only a subset of all acute ischaemic stroke patients with known AF before stroke is (sufficiently) anticoagulated when stroke occurs, as demonstrated in multiple observational studies. <ref type="bibr" target="#b7">7,</ref><ref type="bibr" target="#b8">8</ref></s><s>Insufficient long-term persistence to VKAs or NOACs is another major problem in stroke patients. <ref type="bibr" target="#b9">9,</ref><ref type="bibr" target="#b10">10</ref></s><s>]<ref type="bibr" target="#b3">[3]</ref> Stroke in patients with AF is more often disabling and associated with increased morbidity and mortality compared with stroke in patients without AF. <ref type="bibr" target="#b11">11</ref></s><s>In addition to the reduction of stroke risk, the intake of VKA reduces stroke severity and improves long-term outcome if the international normalized ratio (INR) is within therapeutic range at stroke onset. <ref type="bibr" target="#b8">8,</ref><ref type="bibr" target="#b12">12</ref></s><s>One could argue that there might be a similar effect of pre-admission NOAC intake on stroke-related morbidity and mortality but there is-besides a retrospective analysis including nine patients with NOAC intake before ischaemic strokeno published analysis so far. <ref type="bibr" target="#b13">13,</ref><ref type="bibr" target="#b14">14</ref></s><s>Interestingly, recently published experimental data showed a beneficial effect of rivaroxaban pretreatment on stroke severity in rats. <ref type="bibr" target="#b15">15</ref></s><s>Consequently, we analysed this assumption in a cohort of stroke patients consecutively admitted at our department within 3 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>This single-centre observational study was conducted at the Department of Neurology, Charite ´-Universit€ atsmedizin Berlin and approved by the local Ethics Committee (EA2/022/15).</s><s>Medical records of 3669 patients consecutively admitted to the stroke unit of the Department of Neurology, Charite ´-Universit€ atsmedizin Berlin, Campus Benjamin Franklin, between 1 January 2013 and 31 December 2015 were retrospectively analysed.</s><s>Patients suffering an ischaemic stroke or transient ischaemic attack (TIA) (labeled as 'index stroke') were identified by using relevant ICD-10 discharge diagnoses (I63.x;</s><s>G45.x).</s><s>All patients with ischaemic stroke or TIA and known AF before admission for their index stroke were included in the primary analysis.</s><s>We did not include patients suffering from haemorrhagic stroke.</s><s>The following information was assessed from medical records: demographic details, cardiovascular risk factors (e.g.</s><s>7]<ref type="bibr" target="#b18">[18]</ref> Severe stroke was defined as NIHSS &gt; _ 11 points. <ref type="bibr" target="#b8">8</ref></s><s>Poor functional outcome was defined as mRS &gt; 2 at hospital discharge.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The results are reported as frequencies and percentages for categorical variables.</s><s>In the case of continuous variables, mean and standard deviation (SD) are reported for sufficiently normally distributed data (jskewnessj &lt; 1) or median and inter-quartile range (IQR) for quantitatively skewed variables.</s><s>Differences regarding baseline parameters between patients with different pre-stroke antithrombotic medication were tested using either v 2 , Fisher's exact test, or Student's t-test for independent samples (Table <ref type="table" target="#tab_0">1</ref>).</s><s>First, we tested overall differences between six cohorts using v 2 test or one-way ANOVA (for age).</s><s>In case of P &lt; _ 0.1, we performed post-hoc exploratory tests for the NOAC cohort vs. other cohorts.</s><s>A two sided significance-level of a = 0.05 was applied.</s><s>Severe stroke (NIHSS &gt; _ 11) and poor functional outcome (mRS &gt; 2) were the main outcomes.</s><s>P-values testing different characteristics with regard to these outcomes were age-adjusted using binary logistic regression models (Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>).</s><s>In multiple logistic regression, associations between antithrombotic treatment and stroke severity at admission and functional outcome at discharge were tested after adjustment for age, sex, diabetes mellitus, previous stroke, coronary artery disease, congestive heart failure, peripheral artery disease, renal insufficiency, epilepsy, and malignant tumour (Table <ref type="table" target="#tab_1">2</ref>).</s><s>In addition, endovascular treatment was added to the model regarding the functional outcome at hospital discharge.</s><s>Stroke severity and iv thrombolysis however are affected by oral anticoagulation at stroke onset and have an impact on functional outcome.</s><s>Instead of being mere confounders, they are factors on the 'causal pathway' from anticoagulation treatment to functional outcome at discharge and cannot simply be adjusted for in multiple regression analysis. <ref type="bibr" target="#b19">19</ref></s><s>Therefore, we performed a structural equation analysis to evaluate the causal relationship between anticoagulatory treatment, NIHSS score on admission as well as iv thrombolysis and functional outcome at hospital discharge (Supplementary material online, Figure <ref type="figure">S1</ref>).</s><s>Odds ratios (OR) with 95% confidence intervals (CI) are reported.</s><s>Despite of comparably small groups, we performed a sensitivity analysis comparing NOAC patients with or without altered routine anticoagulation tests to those patients without medical stroke prevention.</s><s>Data were analysed using SPSS statistics 23 and SPSS AMOS 24 (IBM Corp., Armonk, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Out of 3669 patients suffering from acute ischaemic stroke or TIA, 671 (18.3%) had a medical history of AF before index stroke.</s><s>Sixteen patients had a CHA 2 DS 2 -VASc score &lt; 2 and were not included in further analysis because anticoagulation was not (definitively)</s></p><p><s>What's new?</s></p><p><s>• Despite the availability of non-vitamin K-dependent oral anticoagulants, there is a significant under-treatment in primary and secondary stroke prevention in patients with known atrial fibrillation and a CHA 2 DS 2 -VASc score &gt; _ 2 presenting with acute ischaemic stroke in a German university hospital.</s></p><p><s>• The intake of a non-vitamin K-dependent oral anticoagulant before stroke onset reduces the probability of severe stroke on hospital admission as well as poor functional outcome at hospital discharge, as similarly demonstrated for phenprocoumon treated patients with an international normalized ratio &gt; _ 2 on hospital admission.</s><s><ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Comparing patient cohorts receiving a NOAC, VKA, platelet inhibitor or no medical stroke prevention to each other, significant differences were observed regarding age, gender, previous stroke as well as co-existing heart failure, thrombolysis on admission, NIHSS as well as mRS on admission (Table <ref type="table" target="#tab_0">1</ref>).</s><s>A reduced dose of rivaroxaban as well as apixaban was prescribed in 61% and 49% of the respective patient cohort (Supplementary material online, Table <ref type="table" target="#tab_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of oral anticoagulants on stroke severity on admission</head><p><s>On hospital admission, 190 (29.0%) out of 655 patients with known AF and a CHA 2 DS 2 -VASc score &gt; _ 2 before the index stroke had a NIHSS &gt; _ 11 indicating severe stroke.</s><s>In bivariate analysis, old age, female sex, co-existing heart failure, coronary artery disease, and malignant tumour were associated with a higher probability of severe stroke on admission (Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>).</s><s>After adjustment for confounders, VKA intake resulting in an INR &gt; _ 2 on admission [OR 0.23 (95% CI 0.10-0.53)]</s><s>as well as NOAC intake [OR 0.48 (95% CI 0.27-0.86)]</s><s>were inversely associated with severe stroke on admission when compared with patients without antithrombotic medication at stroke onset (Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of oral anticoagulants on functional outcome at hospital discharge</head><p><s>Comparing patient cohorts receiving different therapeutic regimens before admission, significant differences were observed regarding the rate of intravenous thrombolysis and NIHSS score on admission but not regarding the duration of the in-hospital stay (Table <ref type="table" target="#tab_0">1</ref>).</s><s>At discharge, 342 (52.2%) out of 655 patients with known AF and a CHA 2 DS 2 -VASc score &gt; _ 2 before the index stroke had a mRS &gt; 2 indicating poor functional outcome.</s><s>In bivariate analysis, old age, coexisting diabetes, heart failure, and higher NIHSS score on admission were associated with poor functional outcome (Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>).</s><s>In multivariable analysis, VKA intake resulting in an INR &gt; _ 2 on admission [OR 0.33 (95% CI 0.17-0.64)]</s><s>as well as NOAC intake [OR 0.49 (95% CI 0.28-0.86)]</s><s>were inversely associated with poor functional outcome at hospital discharge when compared with patients without antithrombotic medication at stroke onset (Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence regarding NOAC intake before admission</head><p><s>According to documented patient statements, NOAC intake was not discontinued immediately before admission in 159 AF patients.</s><s>Patient-reported daily dose and the results of routine coagulation tests (INR, aPTT, or thrombin time) on admission are depicted in Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>.</s><s>Overall, 90 (56.6%)</s><s>NOAC patients had altered routine coagulation tests indicating an anticoagulatory effect at stroke onset.</s><s>Compared with patients without antithrombotic medication, NOAC patients with altered coagulation tests had a significantly lower rate of severe stroke (NIHSS &gt; _ 11) on admission (18.9% vs. 40.4%;</s><s>OR 0.41 (95% CI 0.20-0.83)</s><s>adjusted for age, sex, coronary artery disease, malignant tumour, peripheral artery disease, heart failure), while NOAC patients without altered coagulation tests had a non-significant lower rate of severe stroke (26.1%; adjusted OR 0.62 (95% CI 0.31-1.25).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>One of the major findings of this study is that only half of the patients with known AF and a CHA 2 DS 2 -VASc score &gt; _ 2 before stroke were   <ref type="table" target="#tab_1">S2</ref>).</s></p><p><s>b Including fondaparinux (n = 3) or therapeutic dose heparin iv (n = 2).</s></p><p><s>taking oral anticoagulation despite given indication.</s><s>This finding underlines the present shortcomings in primary and secondary stroke prevention in AF patients and furthermore demonstrates subsequent complications.</s><s>However, we analysed only AF patients with acute ischaemic stroke; therefore, we cannot draw conclusions on the quality of stroke prevention in AF patients in the general population.</s></p><p><s>Compared with AF patients without antithrombotic medication before stroke (Table <ref type="table" target="#tab_1">2</ref>), self-reported NOAC intake pre-admission lowered the probability of severe ischaemic stroke on hospital admission, as similarly observed for phenprocoumon patients with an INR &gt; _ 2 on admission.</s><s>In accordance with previous publications, there was no significant effect of VKA intake with an INR &lt; 2 or the intake of platelet inhibitors on stroke severity on admission. <ref type="bibr" target="#b8">8,</ref><ref type="bibr" target="#b20">20</ref></s><s>OAC intake also lowered the probability of worse functional outcome at hospital discharge (Table <ref type="table" target="#tab_1">2</ref>), despite of a higher rate of previous stroke and a lower rate of thrombolysis in patients taking a NOAC when compared with AF patients without antithrombotic medication (Table <ref type="table" target="#tab_0">1</ref>).</s><s>A similar effect on stroke severity at hospital discharge was observed in VKA patients with an INR &gt; _ 2 on admission (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Adjusted for various confounders, the multiple relations of stroke severity on admission, thrombolysis as well as endovascular treatment on functional outcome at hospital discharge are depicted in the Supplementary material online, Figure <ref type="figure">S1</ref>.</s><s>As demonstrated, the NIHSS score on admission significantly impacts on the mRS score at discharge.</s><s>Moreover, intake of phenprocoumon or NOAC was inversely related to stroke severity on admission, as indicated by the negative estimates.</s></p><p><s>NOACs are effective in primary and secondary stroke prevention without need for routine coagulation monitoring. <ref type="bibr" target="#b4">4</ref></s><s>However, a non-temporal correlation was reported between (single) plasma concentrations of dabigatran and edoxaban and cerebrovascular events during follow-up of the respective phase III clinical trials. <ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b22">22</ref></s><s>ust recently, a single-centre case series including 19 patients admitted for acute stroke while taking dabigatran demonstrated that plasma concentrations of dabigatran were higher in four patients with intracerebral haemorrhage compared with 15 patients with ischaemic stroke. <ref type="bibr" target="#b23">23</ref></s><s>Because NOAC plasma concentrations on admission or measurements of calibrated anti-Xa activity were not available in our stroke cohort, coagulation tests on hospital admission were analysed (as similarly reported in a German registry). <ref type="bibr" target="#b24">24</ref></s><s>Despite uncertain sensitivity and specificity, these tests provide useful information to assess a residual anticoagulant effect of NOACs-in patients with abnormal results-indicating a recent intake. <ref type="bibr" target="#b25">25</ref></s><s>Of note, NOAC patients with elevated routine coagulation tests had a significantly lower probability of severe stroke when compared to patients without antithrombotic medication on admission.</s><s>This was not the case for NOAC patients without elevated routine coagulation tests.</s><s>With regard to the published phase III randomized trials, the reduced dose of rivaroxaban as well as apixaban was more often prescribed in our stroke cohort (Supplementary material online, Table <ref type="table" target="#tab_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations of the present study</head><p><s>Beside the reported strengths, our study has weaknesses that mitigate the validity of its results.</s><s>First, this is a retrospective single-centre analysis and we cannot exclude that undocumented factors have influenced the physicians' choice of medical stroke prevention in an individual patient pre-stroke.</s><s>Second, there are limitations in terms of statistical power to the various comparisons due to comparably small patient subgroups.</s><s>Third, there were significant differences between patient subgroups regarding baseline characteristics and acute stroke treatment.</s><s>Despite statistical adjustment, residual bias may still be present.</s><s>Fourth, we were unable to assess the adherence to NOAC intake and the actual anticoagulatory effect at the time of stroke onset in more detail because specific tests like calibrated anti-Xa activity are not part of clinical routine so far. <ref type="bibr" target="#b24">24</ref></s><s>We addressed this issue by comparing NOAC patients with and without altered routine coagulation tests to those patients without medical stroke prevention.</s><s>Fifth, due to retrospective data assessment we were unable to assess the impact of pre-hospital time in therapeutic range (TTR) on stroke severity.</s><s>Since the half-life of phenprocoumon is much longer compared to warfarin, we believe that INR on admission is sufficient to assess the quality of anticoagulation in the last week before stroke. <ref type="bibr" target="#b26">26</ref></s><s>inally, we missed an additional follow-up 3 months after stroke that would have strengthened our results.</s><s>Therefore, our findings have to be validated in larger cohorts of stroke patients with known AF as suggested previously. <ref type="bibr" target="#b13">13</ref></s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>................................................................................................................................................................................................................................................................................................</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>.</head><label></label><figDesc><div><p><s>................................................................................................</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics in 655 patients with known AF, acute ischaemic stroke or TIA and a CHA</s></p></div></figDesc><table><row><cell>2</cell></row><row><cell>2 DS 2 -VASc score</cell></row></table><note><p><s>Cohorts are separated according to medical stroke prevention before the index stroke.Overall test: v2 or Fisher's exact test/one way ANOVA for age, Kruskal-Wallis-Test for hospital stay.aMissingvalues:</s><s>n = 3. b Individualized treatment decision after obtaining informed consent in four patients with normal PTT and INR.NOAC intake &lt;24 h was not known at the time of treatment in two patients.NOACs impact on stroke severity indicated before the index stroke.Baseline characteristics of 655 patients with known AF and a CHA 2 DS 2 -VASc score &gt; _ 2 before the index stroke are depicted in Table1.</s><s>In total,</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Adjusted a odds ratios and 95% CI for antithrombotic medication taken prior to admission with regard to severe stroke on hospital admission (NIHSS 11) and poor functional outcome at hospital discharge (mRS &gt; 2) in 655 AF patients with acute ischaemic stroke or TIA and a CHA 2 DS 2 -VASc score 2 before admission Multiple logistic regression analysis was adjusted for: age, sex, diabetes mellitus, previous stroke, coronary artery disease, congestive heart failure, peripheral artery disease, renal insufficiency, epilepsy, malignant tumour, and additionally for endovascular treatment in the model for mRS &gt; 2 at discharge (Supplementary material online, Table</s></p></div></figDesc><table><row><cell></cell><cell>NIHSS 11</cell><cell>mRS &gt; 2</cell></row><row><cell></cell><cell>On admission</cell><cell>At discharge</cell></row><row><cell>Nagelkerke R 2</cell><cell>0.14</cell><cell>0.23</cell></row><row><cell>No antithrombotic medication</cell><cell>1 [reference]</cell><cell>1 [reference]</cell></row><row><cell>Platelet inhibitors</cell><cell cols="2">0.80 (0.47-1.34) 0.82 (0.47-1.42)</cell></row><row><cell>Heparin, low-dose</cell><cell cols="2">0.41 (0.12-1.41) 0.39 (0.13-1.18)</cell></row><row><cell>VKA</cell><cell></cell><cell></cell></row><row><cell>INR &lt; 2</cell><cell cols="2">0.62 (0.33-1.16) 0.61 (0.32-1.16)</cell></row><row><cell>INR &gt; _ 2</cell><cell cols="2">0.23 (0.10-0.53) 0.33 (0.17-0.65)</cell></row><row><cell>NOAC</cell><cell cols="2">0.48 (0.27-0.86) 0.47 (0.27-0.84)</cell></row><row><cell>Other anticoagulants b</cell><cell cols="2">0.59 (0.06-5.76) 0.66 (0.10-4.52)</cell></row></table><note><p><s>a</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank Julia Herde (CSB) for critically reviewing the manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary material</head><p><s>Supplementary material is available at Europace online.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>January</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Wann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Alpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Calkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cigarroa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Cleveland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society</title>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="e1" to="76" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kirchhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benussi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kotecha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Atar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Casadei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1609" to="1678" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<ptr target="http://www.awmf.org/uploads/tx_szleitlinien/030-133l_S3_Sekun€arprophylaxe_isch€amischer_Schlaganfall_2015-02.pdf" />
		<title level="m">Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): S3-Leitlinie Sekund€ arprophylaxe isch€ amischer Schlaganfall und transitorische isch€ amische Attacke</title>
				<imprint>
			<date type="published" when="2016-12-19">19 December 2016</date>
		</imprint>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Comparison of the efficacy and safety of new oral anticoagulants with NOACs impact on stroke severity warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Ruff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Giugliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Deenadayalu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Ezekowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="page" from="955" to="962" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Underuse of oral anticoagulants in atrial fibrillation: a systematic review</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Ogilvie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Welner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="638" to="645" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany-results from the German AFNET registry</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Haeusler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gerth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Limbourg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Tebbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oeff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wegscheider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Neurol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">129</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Glader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stegmayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Norrving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Terent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hulter-Asberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Wester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">255</biblScope>
			<biblScope unit="page" from="22" to="32" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Impact of anticoagulation before stroke on stroke severity and long-term survival</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Haeusler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Konieczny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Endres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">U</forename><surname>Heuschmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Stroke</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="544" to="550" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Glader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sjolander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="397" to="401" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Katholing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wallenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Freedman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="31" to="39" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Marini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sacco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Olivieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Totaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1115" to="1119" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Arsava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Audebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Crowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ni</forename><surname>Chroinin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Stroke</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="808" to="814" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants</title>
		<author>
			<persName><forename type="first">C</forename><surname>Stollberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Finsterer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neurochir Pol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="136" to="140" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Severity and functional outcome of patients with cardioembolic stroke occurring during nonvitamin K antagonist oral anticoagulant treatment</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hagii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Metoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shiroto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hitomi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Stroke Cerebrovasc Dis</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1430" to="1437" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and antiinflammatory mechanism</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dittmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kraft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Schuhmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fluri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kleinschnitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="835" to="843" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Camm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Caterina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Savelieva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Atar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hohnloser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1385" to="1413" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Measurements of acute cerebral infarction: a clinical examination scale</title>
		<author>
			<persName><forename type="first">T</forename><surname>Brott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename><surname>Olinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Marler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Barsan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Biller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="864" to="870" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Interobserver agreement for the assessment of handicap in stroke patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Van Swieten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Koudstaal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schouten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Gijn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="604" to="607" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Confounding and confounders</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mcnamee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Occup Environ Med</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="227" to="234" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Preadmission oral anticoagulant therapy and clinical outcome in patients hospitalised with acute stroke and atrial fibrillation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Ottosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Svendsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Husted</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dan Med J</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page">A4904</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lehr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haertter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Eikelboom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="321" to="328" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Ruff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Giugliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Morrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Kuder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="2288" to="2295" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Dabigatran plasma levels in acute cerebrovascular events</title>
		<author>
			<persName><forename type="first">B</forename><surname>Volbers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kohrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kallmunzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kurka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Breuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ringwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Stroke Cerebrovasc Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="877" to="882" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Purrucker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rizos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Poli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kraft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="152" to="158" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Laboratory measurement of the direct oral anticoagulants</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Dale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Eikelboom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="315" to="336" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kristiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Dahler-Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dahler-Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Brandslund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thromb Res</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="157" to="163" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Hellwig</surname></persName>
		</author>
		<idno type="DOI">10.1093/europace/euy023</idno>
		<imprint>
			<date type="published" when="2018-02-09">9 February 2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Erratum to: Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart rhythm Society (HRS)</title>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1909" to="1922" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Tatjana Potpara had not been mentioned among the members of the ESC Scientific Document Group, and another member had been added erroneously. This has now been corrected online. The Editors apologise for this error</title>
		<idno type="DOI">10.1093/europace/eux252</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Published on behalf of the European Society of Cardiology. All rights reserved. V C The Author(s) 2018. For permissions</title>
		<imprint/>
	</monogr>
	<note>please email: journals.permissions@oup.com</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
